Shares in Dipexium Pharmaceutical (NSDQ:DPRX) dived 84% today after it reported that its OneStep-1 and OneStep-2 Phase III clinical trials of Locilex in patients with mild infections of diabetic foot ulcers did not meet its primary or secondary clinical endpoints.
Both trials failed to show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm, and neither trial demonstrated a higher rate of eradication of bacteria using Locilex. The New York-based company also reported serious adverse events with Locilex, a pexiganan cream at 0.8%, including higher than anticipated rates of osteomyelitis and cellulitis.
Get the full story at our sister site, Drug Delivery Business News.
The post Dipexium crashes after Locilex Phase III trials fail appeared first on MassDevice.
from MassDevice http://ift.tt/2eG1c9T
Cap comentari:
Publica un comentari a l'entrada